Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 17 · below the Ichimoku cloud · RSI 24 (oversold) · MACD below its signal
| 2.04 | 52-week high | +399.51% |
| 0.7100 | Previous month high | +73.85% |
| 0.5900 | Previous week high | +44.47% |
| 0.5700 | Previous month low | +39.57% |
| 0.5210 | Previous week low | +27.57% |
| 0.4687 | R3 (classic) | +14.76% |
| 0.4493 | R2 (classic) | +10.02% |
| 0.4300 | Previous day high | +5.29% |
| 0.4287 | R1 (classic) | +4.96% |
| 0.4093 | Pivot | +0.23% |
| 0.4084 | Price now | |
| 0.3900 | Previous day low | −4.51% |
| 0.3887 | S1 (classic) | −4.83% |
| 0.3693 | S2 (classic) | −9.57% |
| 0.3600 | 52-week low | −11.85% |
| 0.3487 | S3 (classic) | −14.63% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.2M | 0.00% | 4.28M | +15% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TNYA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | Ali FarazChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 122K | — |
| Sep 9, 2026 | Tingley WhittemoreOfficer | Stock Award(Grant) at price 0.00 per share. | 49K | — |
| Aug 16, 2026 | Ali FarazChief Executive Officer | Sale at price 0.71 per share. | 22.2K | $15.78K |
| Aug 16, 2026 | Tingley WhittemoreOfficer | Sale at price 0.71 per share. | 7.4K | $5.27K |
| May 17, 2026 | Ali FarazChief Executive Officer | Sale at price 0.79 per share. | 3.4K | $2.69K |
| May 17, 2026 | Tingley WhittemoreOfficer | Sale at price 0.79 per share. | 3.1K | $2.48K |
| May 17, 2026 | Higa TomohiroOfficer | Sale at price 0.79 per share. | 1.5K | $1.18K |
| Feb 24, 2026 | Column Group Iii Gp, L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.56 - 0.62 per share. | 4.17M | $2.38M |
| Feb 22, 2026 | Column Group Iii Gp, L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.60 - 0.61 per share. | 829.7K | $504.79K |
| Feb 16, 2026 | Ali FarazChief Executive Officer | Sale at price 0.64 per share. | 14.9K | $9.56K |
| Feb 16, 2026 | Tingley WhittemoreOfficer | Sale at price 0.64 per share. | 5.2K | $3.32K |
| Feb 16, 2026 | Higa TomohiroOfficer | Sale at price 0.64 per share. | 3.5K | $2.23K |
| Feb 10, 2026 | Column Group Iii Gp, L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 0.68 - 0.82 per share. | 4.40M | $3.04M |
| Feb 2, 2026 | Ali FarazChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 158.6K | — |
| Feb 2, 2026 | Tingley WhittemoreOfficer | Stock Award(Grant) at price 0.00 per share. | 48.8K | — |
| Feb 2, 2026 | Higa TomohiroOfficer | Stock Award(Grant) at price 0.00 per share. | 29.3K | — |
| Nov 16, 2025 | Ali FarazChief Executive Officer | Sale at price 1.33 per share. | 3.1K | $4.16K |
| Nov 16, 2025 | Tingley WhittemoreOfficer | Sale at price 1.33 per share. | 2.9K | $3.83K |
| Nov 16, 2025 | Higa TomohiroOfficer | Sale at price 1.33 per share. | 1.4K | $1.82K |
| Aug 17, 2025 | Ali FarazChief Executive Officer | Sale at price 1.25 per share. | 14.5K | $18.21K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.8 | -27.5 | 23.1 | -0.1 | 25.8 | -15.0 | 0.1 | -7.0 | -12.2 | -32.4 | −42.6% | ||
| 2025 | -25.9 | -4.7 | -43.6 | -16.7 | -3.2 | 32.8 | 10.6 | 67.2 | 43.4 | -11.1 | -2.8 | -49.1 | −50.2% |
| 2024 | 29.8 | 41.5 | -12.1 | -13.2 | -7.3 | -26.4 | 12.9 | -23.4 | -28.0 | -0.5 | 85.9 | -59.9 | −55.9% |
| 2023 | 70.1 | -10.2 | -7.2 | 86.5 | 35.5 | -18.5 | -17.5 | -20.0 | -34.1 | -28.6 | 3.3 | 72.3 | +61.2% |
| 2022 | -37.1 | -2.2 | 1.0 | -21.7 | -27.3 | -16.0 | -15.3 | -8.0 | -33.9 | -7.6 | -1.1 | -24.2 | −89.4% |
| 2021 | 31.9 | 2.0 | 24.5 | -23.6 | -3.6 | +23.5% |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Buy / hold / sell counts